Inventiva (NASDAQ:IVA) Announces Earnings Results, Misses Expectations By $0.57 EPS

Inventiva (NASDAQ:IVA) released its quarterly earnings data on Monday. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.57), FiscalAI reports. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $8.67 million.

Inventiva Price Performance

Shares of IVA traded down $0.24 during mid-day trading on Monday, hitting $5.48. 286,516 shares of the company’s stock were exchanged, compared to its average volume of 434,234. Inventiva has a fifty-two week low of $2.85 and a fifty-two week high of $7.98. The business’s 50 day moving average is $6.30 and its two-hundred day moving average is $5.38.

Wall Street Analysts Forecast Growth

IVA has been the subject of several research reports. HC Wainwright set a $24.00 target price on Inventiva and gave the company a “buy” rating in a report on Wednesday, January 28th. Leerink Partners started coverage on Inventiva in a research note on Monday, January 12th. They set an “outperform” rating and a $12.00 price target on the stock. UBS Group began coverage on Inventiva in a research report on Wednesday, January 7th. They set a “buy” rating and a $12.00 price target on the stock. Truist Financial started coverage on Inventiva in a research note on Thursday, March 19th. They issued a “buy” rating and a $13.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a report on Thursday, January 22nd. Three analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Inventiva presently has a consensus rating of “Buy” and a consensus target price of $16.56.

Institutional Trading of Inventiva

Several institutional investors and hedge funds have recently added to or reduced their stakes in IVA. Creative Planning purchased a new stake in shares of Inventiva during the second quarter worth approximately $32,000. Commonwealth Equity Services LLC grew its position in Inventiva by 19.6% in the 4th quarter. Commonwealth Equity Services LLC now owns 77,561 shares of the company’s stock valued at $361,000 after buying an additional 12,704 shares during the last quarter. Virtu Financial LLC purchased a new position in Inventiva in the 4th quarter valued at $60,000. XTX Topco Ltd acquired a new position in Inventiva in the 4th quarter valued at $84,000. Finally, NewEdge Advisors LLC purchased a new position in Inventiva during the 3rd quarter worth $116,000. 19.06% of the stock is owned by hedge funds and other institutional investors.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.